Systolic Heart Failure
ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration
This Study involves research about a product called “CAP-1002 Allogeneic Cardiosphere-Derived Cells” (“CAP-1002”). CAP-1002 is a biologic product consisting largely of cells grown from donated human heart muscle tissue. The purpose of this Study is to evaluate the safety and effectiveness of CAP-1002 in the treatment and/or prevention of left ventricular (LV) dysfunction following myocardial infarction (MI), also known as a “heart attack”. The Study will also examine whether the use of CAP-1002 can decrease the amount of heart muscle damage and/or improve heart function after a heart attack. The amount of heart muscle damage and the function of the heart directly affect health over time and the development of heart failure and other complications some people experience after a heart attack. In this Study, CAP 1002 is considered to be investigational (not approved by the FDA) for treatment and/or prevention of LV dysfunction following MI.
Principal Investigator: Carl J. Pepine
Please contact our Clinical Trials Office for information: (352) 273-8933